Founded in 2016, Integrated Graphene has developed the world’s only commercially viable graphene manufacturing process that is currently scaled to high volumes. This process eliminates the scale-up challenges associated with CVD graphene and graphene powder. As well as direct manufacturing, Integrated Graphene is designing manufacturing processes for blue-chip companies to effectively bolt-on to existing lines, and it also has a team dedicated to supporting organisations to adapt graphene technologies for their products.

The company’s investment plan will focus on scaling-up the manufacturing of its market-ready graphene enhanced electrodes and super capacitors which are currently being piloted by global blue-chips in human diagnostics point of care testing and smart label asset tracking applications.

As part of its growth plans, the company intends to double its existing footprint in Stirling and treble its headcount to 100 over the next three years, hiring a significant number of market leading development and commercial experts in the UK, Europe and North America.

The company will also increase capital expenditure in its next generation pilot line to allow rapid market expansion of Gii-Sens and Gii-Cap. For Gii-Sens, that includes wearables, animal diagnostics, companion diagnostics, environmental diagnostics. With Gii-Cap, expansion markets include Drones, e-mobility, space, satellites, and wearables.

The investment comes on the back of a significantly oversubscribed Series A + funding round for an undisclosed sum led by existing investors, Par Equity and Archangels.

Claus Marquordt, co-founder and CEO, Integrated Graphene, said: “This investment marks a real tipping point for Integrated Graphene and the manufacturing of our unique 3D Graphene foam in its first two market-ready products. We are actively involved in projects with several global blue-chip companies to deliver high volumes of electrodes and super capacitors that address critical needs in accelerating point of care human diagnostics for a wide range of killer diseases and in enabling low-cost flexible and sustainable power systems for the booming IoT, Smart Label and Wearable tech markets.

“By investing now, we will be ready, this year, to produce millions of units per annum from a new facility in Stirling and to transfer the technology at scale to global partners in the future.”

Aidan MacMillan, senior investment manager at Par Equity, added: “Integrated Graphene has developed a game changing, frontier solution with the potential to drive enormous impact across a range of large-scale industries. As existing investors in the business, Par Equity, and a selection of our advisers, have worked closely with Claus and the team to build the business. We’re delighted to continue our support in this round, to catalyse the team’s ambition and unlock the company’s growth potential.”

Niki Mckenzie, joint managing director at Archangels, commented: “Since we first invested in Integrated Graphene two years ago, the company has moved rapidly from start-up to scale-up and now has its sights focused on meeting increased global demand from multiple sectors. We are looking forward to continuing our relationship with the team, as they embark on this next critical phase of growth.”